First IHRT will bring you up to date on other events NOT happening in Endogyn, then we will share the GREAT news from Karen Steward! 
Ohhhhh! Ahhhhhh!
**No new orders from King Kru to Goldi! (Good thing for Goldi!)
**One "upset" Karen Steward rambling on and on in her ramblings! Nice to see her back as she alone makes the Endogyn message board worth reading! We all need a laugh now and then! Temper, temper Karen!
**One "upset" Karen Steward rambling on and on in her ramblings! Nice to see her back as she alone makes the Endogyn message board worth reading! We all need a laugh now and then! Temper, temper Karen!
** In the "ho-hum" department we see Helen Dynda still picking away at 1000's of URL's and posting them, well,.... to no one actually!
**No telephone or fax contact information for patients from Kru
**No address of any klinik he is doing surgery in, but he is going to Fuldi soon!
**No NEW photos of patients,only undated ones that can be any surgery by any surgeon anywhere! LOL! LOL! ( See how dumb Kru thinks people are!)
**No telephone or fax contact information for patients from Kru
**No address of any klinik he is doing surgery in, but he is going to Fuldi soon!
**No NEW photos of patients,only undated ones that can be any surgery by any surgeon anywhere! LOL! LOL! ( See how dumb Kru thinks people are!)
** Gisela turns from Lisa Gravens to Karen Steward for guidance! (Lisa IS a bit over the top when trying to advocate, but she can't see it, she does have issues of her own if we go by Kru's word! Karen, well, no matter what Karen says, Gisela will never get a surgery with Kru, and IHRT knows that to be a fact! IHRT encourages you to follow as Gisela trys to secure a surgery with Kru!)
**Actually, there is nothing going in Endogyn, absolutely nothin
Like Karen has always said,
" What goes around will come around," & " The truth shall prevail in the end!"
**IHRT must confess that Karen Steward IS correct in stating that there IS a most capable and skilled adhesion surgeon in Germany who does use Spraygel and meticulous hemostasis, and his names does start with a "K," and he IS wonderful, kind, compassionate, honest, trustworthy, and an excellent surgeon who gets excellent results from his adhesiolysis procedure....thanks to Karen for bringing him up once again on the Endogyn board, IHRT will do the same for all you German AND International patients!
Significant Clinical Result in the Treatment of Adhesions with the SprayGel Adhesion Barrier
April 24, 2002
German Case Provides Freedom from Pain for the First Time in 22 Years for a Canadian Woman
Waltham, MA (USA), April 24, 2002:
Confluent Surgical, Inc. announced today that the SprayGel Adhesion Barrier, their flagship product, exceeded the clinical expectations of a leading German gynecologic surgeon in the treatment of a patient suffering from adhesion-related pain for twenty-two years.
Matthias Korell, MD, Privat Dozent of Gynecological Surgery, Duisburg, Germany, is recognized for his expertise in preventing and reducing adhesions in the abdomen and pelvis that result from previous open or laparoscopic surgical intervention.
"The SprayGel Adhesion Barrier exceeded my expectations in reducing adhesions and represents a big step forward in treating patients with adhesion-related pain," says Dr. Korell. "We could see a complete adhesion-free abdominal wall one week after performing adhesiolysis." Adhesiolysis is the surgical removal of adhesions. "Having treated this patient since July 2000 for adhesion-related pain, this is the first and only time that significant improvement from pain has been recognized."
The patient, a Registered Nurse and mother of six from Calgary, Alberta (Canada), has had over twenty abdomino/pelvic surgeries in the last twenty-two years. As a direct result of these surgeries, she had developed adhesions. These adhesions severely impacted her lifestyle as evidenced by her inability to lie down or raise her arms above her head without pain. "The pain controlled my life, resulting in the loss of my job and dramatic feelings of isolation. Other products for adhesion reduction have been used during my past surgeries, but the pain would return in two to three days," said the patient.
Eight days after Dr. Korell’s use of the SprayGel Adhesion Barrier, she refers to her case as "a miracle – I feel very good with an overall sense of wellness and, for the first time in years I have complete mobility without pain." Dr. Korell further stated, "there is no risk of the development of severe adhesions unless she has another traumatic surgery. While this case is of an extreme nature, the performance of the SprayGel Adhesion Barrier supports the benefits of the prevention and reduction of adhesions in routine gynecological surgery that may result in adhesion formation."
Adhesions and fibrous bands of tissue between adjacent organs of the body are typically caused by surgery and are directly related to pain. Adhesions can start to form within three hours after surgery and will cease forming when the sites of surgery heal, typically within seven days following surgery. It is estimated that adhesions affect over five million women and men worldwide and that the global market potential for total abdominopelvic adhesion management is estimated at approximately $2.6 billion (US).
Evidence of adhesion prevention and reduction is discovered when a surgeon takes a second look at the surgical site through a laparoscope, an instrument used to perform less-invasive surgery.
Amar S. Sawhney, Ph.D., founder, President and CEO of Confluent Surgical, Inc., said, "we are very pleased with our clinical results in Europe to date and believe that cases such as Professor Korell’s represent additional evidence that differentiates the SprayGel Adhesion Barrier from all other adhesion barrier products on the market today."
The SprayGel Adhesion Barrier received CE mark in November 2001, and has been introduced in major markets in Europe. Based on a European clinical study, the patented and proprietary synthetic material of the SprayGel Adhesion Barrier has been shown to reduce or eliminate adhesion formation following abdominopelvic surgery. The SprayGel Adhesion Barrier is not commercially available in the United States.
Confluent Surgical, Inc. is a privately held company developing products based on its platform of in-situ polymerized biomaterials and associated delivery systems. For more information please or visit the Confluent Surgical website at www.confluentsurgical.com.
2006 update:
Tyco International, Ltd. Press July 18, 2006
Tyco International Signs Agreement to Acquire Confluent Surgical
PEMBROKE, Bermuda, July 18, 2006 /PRNewswire-FirstCall/
-- Tyco International Ltd. (NYSE: TYC; BSX: TYC) today announced that U.S. Surgical, a subsidiary of Tyco's Healthcare segment, entered into a definitive agreement to acquire Confluent Surgical, Inc., a leading developer and supplier of polymer-based technology used in sprayable surgical sealants and anti-adhesion products. The transaction is priced at $245 million. The Boards of Tyco International and Confluent Surgical have approved the transaction, which is expected to close by the end of August. Tyco expects to incur a charge in its fiscal fourth quarter to write off in-process research and development.
Confluent Surgical, located in Waltham, Mass., markets a neurosurgical sealant that was the first product to receive Food & Drug Administration (FDA) approval for use in cranial dural repair. This sealant, along with several other products in the company's pipeline, is intended to improve patient outcomes by reducing leaks or adhesions across various surgical specialties.
Over the next six years, the bio-surgery market - which is estimated at $900 million - is expected to double in size. This acquisition helps position Tyco Healthcare and U.S. Surgical to compete effectively in that growing market.
More……http://www.tyco.com/livesite/Page/Tyco/Who+We+Are/Press+Center/Press+Releases+Details/??&DCRID=478242496
Chefarzt PD Dr. med. Matthias Korell
GynaecologyHead of the department:
Fone: 0049 203 733 2200
Fax: 0049 203 733 2202e
EMail: m.korell@t-online.de
Tel. secretariat 0203/733 2201
http://translate.google.com/translate?hl=en&sl=de&u=http://www.klinikum-duisburg.de/&sa=X&oi=translate&resnum=1&ct=result&prev=/search%3Fq%3DDuisburg%2Bklinik%26hl%3Den%26sa%3DG
Duisburg Klinik - Germany
Clinical center Duisburg gGmbH
To the deer meadows 947055
DuisburgTelephone (02 03) 7 33-0Fax (02 03) 7 33-10 02
E-Mail:info@klinikum-duisburg.de
http://translate.google.com/translate?hl=en&sl=de&u=http://www.klinikum-duisburg.de/&sa=X&oi=translate&resnum=1&ct=result&prev=/search%3Fq%3DDuisburg%2Bklinik%26hl%3Den%26sa%3DG
**Actually, there is nothing going in Endogyn, absolutely nothin
Like Karen has always said,
" What goes around will come around," & " The truth shall prevail in the end!"
**IHRT must confess that Karen Steward IS correct in stating that there IS a most capable and skilled adhesion surgeon in Germany who does use Spraygel and meticulous hemostasis, and his names does start with a "K," and he IS wonderful, kind, compassionate, honest, trustworthy, and an excellent surgeon who gets excellent results from his adhesiolysis procedure....thanks to Karen for bringing him up once again on the Endogyn board, IHRT will do the same for all you German AND International patients!
Significant Clinical Result in the Treatment of Adhesions with the SprayGel Adhesion Barrier
April 24, 2002
German Case Provides Freedom from Pain for the First Time in 22 Years for a Canadian Woman
Waltham, MA (USA), April 24, 2002:
Confluent Surgical, Inc. announced today that the SprayGel Adhesion Barrier, their flagship product, exceeded the clinical expectations of a leading German gynecologic surgeon in the treatment of a patient suffering from adhesion-related pain for twenty-two years.
Matthias Korell, MD, Privat Dozent of Gynecological Surgery, Duisburg, Germany, is recognized for his expertise in preventing and reducing adhesions in the abdomen and pelvis that result from previous open or laparoscopic surgical intervention.
"The SprayGel Adhesion Barrier exceeded my expectations in reducing adhesions and represents a big step forward in treating patients with adhesion-related pain," says Dr. Korell. "We could see a complete adhesion-free abdominal wall one week after performing adhesiolysis." Adhesiolysis is the surgical removal of adhesions. "Having treated this patient since July 2000 for adhesion-related pain, this is the first and only time that significant improvement from pain has been recognized."
The patient, a Registered Nurse and mother of six from Calgary, Alberta (Canada), has had over twenty abdomino/pelvic surgeries in the last twenty-two years. As a direct result of these surgeries, she had developed adhesions. These adhesions severely impacted her lifestyle as evidenced by her inability to lie down or raise her arms above her head without pain. "The pain controlled my life, resulting in the loss of my job and dramatic feelings of isolation. Other products for adhesion reduction have been used during my past surgeries, but the pain would return in two to three days," said the patient.
Eight days after Dr. Korell’s use of the SprayGel Adhesion Barrier, she refers to her case as "a miracle – I feel very good with an overall sense of wellness and, for the first time in years I have complete mobility without pain." Dr. Korell further stated, "there is no risk of the development of severe adhesions unless she has another traumatic surgery. While this case is of an extreme nature, the performance of the SprayGel Adhesion Barrier supports the benefits of the prevention and reduction of adhesions in routine gynecological surgery that may result in adhesion formation."
Adhesions and fibrous bands of tissue between adjacent organs of the body are typically caused by surgery and are directly related to pain. Adhesions can start to form within three hours after surgery and will cease forming when the sites of surgery heal, typically within seven days following surgery. It is estimated that adhesions affect over five million women and men worldwide and that the global market potential for total abdominopelvic adhesion management is estimated at approximately $2.6 billion (US).
Evidence of adhesion prevention and reduction is discovered when a surgeon takes a second look at the surgical site through a laparoscope, an instrument used to perform less-invasive surgery.
Amar S. Sawhney, Ph.D., founder, President and CEO of Confluent Surgical, Inc., said, "we are very pleased with our clinical results in Europe to date and believe that cases such as Professor Korell’s represent additional evidence that differentiates the SprayGel Adhesion Barrier from all other adhesion barrier products on the market today."
The SprayGel Adhesion Barrier received CE mark in November 2001, and has been introduced in major markets in Europe. Based on a European clinical study, the patented and proprietary synthetic material of the SprayGel Adhesion Barrier has been shown to reduce or eliminate adhesion formation following abdominopelvic surgery. The SprayGel Adhesion Barrier is not commercially available in the United States.
Confluent Surgical, Inc. is a privately held company developing products based on its platform of in-situ polymerized biomaterials and associated delivery systems. For more information please or visit the Confluent Surgical website at www.confluentsurgical.com.
2006 update:
Tyco International, Ltd. Press July 18, 2006
Tyco International Signs Agreement to Acquire Confluent Surgical
PEMBROKE, Bermuda, July 18, 2006 /PRNewswire-FirstCall/
-- Tyco International Ltd. (NYSE: TYC; BSX: TYC) today announced that U.S. Surgical, a subsidiary of Tyco's Healthcare segment, entered into a definitive agreement to acquire Confluent Surgical, Inc., a leading developer and supplier of polymer-based technology used in sprayable surgical sealants and anti-adhesion products. The transaction is priced at $245 million. The Boards of Tyco International and Confluent Surgical have approved the transaction, which is expected to close by the end of August. Tyco expects to incur a charge in its fiscal fourth quarter to write off in-process research and development.
Confluent Surgical, located in Waltham, Mass., markets a neurosurgical sealant that was the first product to receive Food & Drug Administration (FDA) approval for use in cranial dural repair. This sealant, along with several other products in the company's pipeline, is intended to improve patient outcomes by reducing leaks or adhesions across various surgical specialties.
Over the next six years, the bio-surgery market - which is estimated at $900 million - is expected to double in size. This acquisition helps position Tyco Healthcare and U.S. Surgical to compete effectively in that growing market.
More……http://www.tyco.com/livesite/Page/Tyco/Who+We+Are/Press+Center/Press+Releases+Details/??&DCRID=478242496
Chefarzt PD Dr. med. Matthias Korell
GynaecologyHead of the department:
Fone: 0049 203 733 2200
Fax: 0049 203 733 2202e
EMail: m.korell@t-online.de
Tel. secretariat 0203/733 2201
http://translate.google.com/translate?hl=en&sl=de&u=http://www.klinikum-duisburg.de/&sa=X&oi=translate&resnum=1&ct=result&prev=/search%3Fq%3DDuisburg%2Bklinik%26hl%3Den%26sa%3DG
Duisburg Klinik - Germany
Clinical center Duisburg gGmbH
To the deer meadows 947055
DuisburgTelephone (02 03) 7 33-0Fax (02 03) 7 33-10 02
E-Mail:info@klinikum-duisburg.de
http://translate.google.com/translate?hl=en&sl=de&u=http://www.klinikum-duisburg.de/&sa=X&oi=translate&resnum=1&ct=result&prev=/search%3Fq%3DDuisburg%2Bklinik%26hl%3Den%26sa%3DG
No comments:
Post a Comment